Eiko Lifesciences Board of Directors
Get the latest insights into the leadership at Eiko Lifesciences. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Laxmikant Ramprasad Kabra | Chairman & Non-Exe.Director |
| Mr. Sumukh Vartak | Whole Time Director |
| Mr. Bhavesh Dhirajlal Tanna | Non Executive Director |
| Ms. Hasti Doshi | Independent Director |
| Ms. Kajal Dhanpatraj Kothari | Independent Director |
| Mr. Rajkumar Govindas Baheti | Independent Director |
Eiko Lifesciences Share price
EIKO
51.31
0.71 (-1.36%)Last updated on 4 Sep, 2025 | 15:29 IST
BUYSELL
Today's High
52.02
Today's Low
50.75
52 Week Low
42.00
52 Week High
74.88
The current prices are delayed, login to your account for live prices
LoginEiko Lifesciences FAQs
The board at Eiko Lifesciences consists of experienced professionals, including Mr. Laxmikant Ramprasad Kabra , Mr. Sumukh Vartak , and others, overseeing the company’s strategic and corporate governance.
Directors at Eiko Lifesciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Laxmikant Ramprasad Kabra is the current chairman at Eiko Lifesciences.
Executive directors at Eiko Lifesciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Eiko Lifesciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Eiko Lifesciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.